ARCH — Arch Biopartners Income Statement
0.000.00%
Last trade - 00:00
- CA$152.50m
- CA$157.23m
- CA$1.98m
R2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.094 | 0.068 | 3.89 | 0.965 | 1.98 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Operating Interest Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.19 | 4.7 | 5.05 | 2.35 | 5.34 |
Operating Profit | -2.1 | -4.63 | -1.16 | -1.39 | -3.36 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -2.09 | -4.63 | -1.17 | -1.41 | -3.33 |
Net Income After Taxes | -2.09 | -4.63 | -1.17 | -1.41 | -3.33 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.09 | -4.63 | -1.17 | -1.41 | -3.33 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.09 | -4.63 | -1.17 | -1.41 | -3.33 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.036 | -0.077 | -0.019 | -0.023 | -0.053 |